#United States #Boston #Canavan Disease #Myrtelle #MYR-101

Myrtelle to Present Clinical Data on MYR-101 Gene Therapy

Myrtelle, Inc., a pioneer in gene therapy development, is set to make a significant impact at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting from May 11 to 14, 2026. This conference marks a crucial platform for the company to unveil clinical data and regulatory advancements related to their innovative MYR-101 gene therapy program for Canavan disease, a serious neurodegenerative condition predominantly affecting children.

Presentation Highlights

During the conference, Dr. Paola Leone, a globally acknowledged expert in Canavan disease and a scientific adviser for Myrtelle, will present a session titled "Beyond Neurons: Glial-targeted Gene and Cell Therapies for Neurologic and Ophthalmic Diseases." This presentation, scheduled for Tuesday, May 12, from 3:30 PM to 5:00 PM ET, will delve into the clinical data from the ongoing trials of Myrtelle’s investigational gene therapy, which targets oligodendrocytes, crucial cells for healthy brain function.

"It’s an honor to share our findings with the ASGCT community. The data we've gathered from children treated so far shows encouraging signals of therapeutic benefit and clinical improvement," highlighted Dr. Leone. The presentation aims to foster greater understanding and discussion about innovative gene therapies that could redefine treatment pathways for Canavan disease.

Collaborations and Future Paths

Additionally, Adrian Stecyk, the CEO of Myrtelle, will participate as a guest presenter in a luncheon symposium hosted by Viralgen, Myrtelle's commercial manufacturing partner for MYR-101. This session, taking place on Wednesday, May 13, will focus on their collaboration and outline Myrtelle’s involvement in the START Pilot Program, alongside key data insights about their regulatory trajectory towards a Biologics License Application (BLA) submission.

"Collaborating with Viralgen has been an exciting journey, and we’re thrilled to share our progress with the broader gene therapy community at ASGCT," said Stecyk.

About Myrtelle and Canavan Disease

Myrtelle, Inc. is dedicated to transforming the landscape of gene therapy focused on neurodegenerative diseases. With a proprietary platform and portfolio of programs, the company strives to provide innovative therapeutic solutions for patients with unmet medical needs. Currently, Myrtelle has partnered with Pfizer for a comprehensive licensing agreement concerning their Canavan disease initiative.

Canavan disease is characterized by the deficiency of the aspartoacylase enzyme due to mutations in the ASPA gene, leading to severe complications such as significant developmental delays, seizures, and ultimately life-threatening issues. Unfortunately, there are no existing cures, and treatment options remain limited to palliative care, making the work of Myrtelle and similar organizations crucial.

For those interested in learning more about Myrtelle’s clinical trials and research initiatives, detailed information is available at ClinicalTrials.gov under the identifier NCT04833907 or by reaching out via email for further inquiries.

As Myrtelle prepares to present these significant findings, the anticipation builds for advancements in Canavan disease treatment, and the hope that MYR-101 can pave the way for a brighter future for affected children and their families.